GAO urges tougher review of some medical devices

By Lisa Richwine

WASHINGTON (Reuters) - U.S. regulators should make sure high-risk medical devices undergo the agency’s toughest review process before they are allowed on the market, a congressional watchdog report said on Thursday.

The Food and Drug Administration oversees devices ranging from simple bandages and tongue depressors to the most complex such as pacemakers and heart-valve replacements. Each is classified based on the level of risk to patients.

The General Accountability Office said in a report the FDA had cleared more than 200 high-risk devices, known as “class III,” to go through a less stringent review process that was intended for simpler products.

The FDA should “expeditiously” issue regulations that would require the toughest level of review for all products deemed high-risk, the report said.

A Democratic lawmaker said he would hold hearings on the FDA’s device review process and, if needed, develop legislation if needed to protect patients.

“GAO’s investigation confirms my concerns that the approval process for medical devices is woefully inadequate. For years, Congress has required high-risk medical devices to undergo stringent pre-market review, but GAO’s findings show that is simply not happening in every case,” said New Jersey Rep. Frank Pallone, who chairs the health subcommittee of the House of Representatives Energy and Commerce Committee.

The GAO findings were based on devices reviewed between fiscal years 2003 and 2007.

During that time, 228 high-risk devices were approved after the less-stringent review, the GAO said.

The Department of Health and Human Services, the parent agency of the FDA, agreed with the GAO recommendations but did not say when it would address the issue, the report said.

“Given that more than three decades have passed since Congress envisioned that all class III devices would eventually be required to undergo pre-market review through the more stringent (approval) process, it is imperative that FDA take immediate steps,” the GAO said.

FDA spokeswoman Karen Riley said “we’re considering the legal and procedural options to accomplish the objective.”

Diana Zuckerman, president of the National Research Center for Women & Families, said the report showed “the FDA continues to approve products that are not adequately scrutinized to make sure they are safe.”

(Reporting by Lisa Richwine; editing by Richard Chang)

Source

--------------------------------------------------------------------------------------------
Related Posts:


WASHINGTON (Reuters) - The U.S. Food and Drug Administration, hampered by increasing globalization and a rise in complex products, may not be able to adequately protect the public’s health, the watchdog arm of Congress said in new findings released on Thursday. “As a result, the American consumer may not be adequately protected from unsafe and ineffective

Full Post: Report cites FDA’s weaknesses over drugs, devices
--------------------------------------------------------------------------------------------

By Will Boggs, MD NEW YORK (Reuters Health) - Mobile teleconsulting is a feasible way to evaluate remotely located patients who have just had a stroke, according to a report in the current issue of the journal Stroke. Although researchers found that hospital-based, land-line systems still provide better quality communication. In a study involving 2 stroke centers

Full Post: Mobile teleconsulting can evaluate stroke patients
--------------------------------------------------------------------------------------------

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Quicker drug approvals and sophisticated marketing campaigns may be putting more patients at risk of dangerous side-effects but the same techniques might be put to use to protect them, a researcher argued on Tuesday. New U.S. Food and Drug Administration procedures have clearly sped up some drug

Full Post: Aggressive drug marketing may endanger people: study
--------------------------------------------------------------------------------------------

By Julie Steenhuysen CHICAGO (Reuters) - Implantable heart defibrillators — which have been found to save lives in younger patients — appear to have the same benefit for people over 70, U.S. researchers said on Tuesday. The study suggests the devices, known as implantable cardioverter defibrillators or ICDs, should be offered to people in their 70s despite

Full Post: Implantable defibrillators save older patients too
--------------------------------------------------------------------------------------------

NEW YORK (Reuters Health) - Young women who undergo ovarian stimulation so that eggs can be retrieved for donation experience few complications, but some risks remain, New York-based researchers report. “When we recruit a young, healthy woman as an egg donor, we owe her the safest possible care,” investigator Dr. Ina N. Cholst told Reuters Health. “Our

Full Post: Little but not zero risk seen with egg donation

Site Navigation

Most Read

Search